中国临床医学2024,Vol.31Issue(5):844-850,封3,8.DOI:10.12025/j.issn.1008-6358.2024.20240893
177Lu-前列腺特异性膜抗原放射性配体疗法治疗前列腺癌临床应用专家共识
Expert consensus on clinical application of 177Lu-prostate specific membrane antigen radio-ligand therapy in prostate cancer
摘要
Abstract
177Lu-prostate specific membrane antigen(PSMA)radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China.Based on domestic clinical practice and experimental data and referred to international experience and viewpoints,the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.关键词
177Lu标记的前列腺特异性膜抗原/前列腺癌/放射性配体治疗/专家共识Key words
177Lu-prostate specific membrane antigen/prostate cancer/radio-ligand therapy/expert consensus分类
医药卫生引用本文复制引用
刘国兵,霍力,兰晓莉,李彪,缪蔚冰,宋少莉,徐浩,田蓉,罗全勇,王峰,王雪梅,卓维海,杨爱民,戴东,邓智勇,赵晋华,陈晓良,范岩,高再荣,韩星敏,蒋宁一,匡安仁,顾宇参,林岩松,刘甫庚,楼岑,苏新辉,唐立钧,王辉,王欣璐,杨福洲,杨辉,赵新明,杨志,杨波,黄晓冬,陈继亮,李思进,汪静,李亚明,石洪成,陈跃,樊卫,郭剑明,谭建,朱小华..177Lu-前列腺特异性膜抗原放射性配体疗法治疗前列腺癌临床应用专家共识[J].中国临床医学,2024,31(5):844-850,封3,8.基金项目
国家临床重点专科建设项目(YWP2022-007),上海市 2023 年度创新医疗器械应用示范项目(23SHS01200),工业和信息化部 2022 年国家重点研发计划(CEIEC-2022-ZM02-0219).Supported by National Key Clinical Specialty Program of China(YWP2022-007),2023 Shanghai Innovative Medical Device Application Demonstration Project(23SHS01200),2022 Key Program of Ministry of Industry and Information Technology of China(CEIEC-2022-ZM02-0219). (YWP2022-007)